Semaglutide for Weight Management

Candidate profile

Adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea), who have attempted lifestyle modification (diet + exercise) without achieving sufficient results. This mirrors the FDA-approved indication for Wegovy (semaglutide 2.4 mg).

Also relevant for individuals with BMI ≥25 seeking medical weight management through clinical providers offering off-label GLP-1 prescriptions.

Approach

Weekly subcutaneous semaglutide with a structured dose-titration schedule, combined with resistance training for lean mass preservation and dietary protein optimization to mitigate the muscle-loss component of weight reduction.

Titration protocol

Semaglutide requires slow titration to manage GI side effects. Rushing titration is the most common protocol error.

| Week | Dose | Notes |

|------|------|-------|

| 1–4 | 0.25 mg/week | Initiation dose. GI symptoms (nausea, constipation) are most common here. |

| 5–8 | 0.5 mg/week | First escalation. Appetite suppression becomes noticeable. |

| 9–12 | 1.0 mg/week | Significant appetite reduction for most patients. |

| 13–16 | 1.7 mg/week | Second major escalation. Some patients plateau here. |

| 17+ | 2.4 mg/week | Maximum approved dose. Not all patients need this level. |

Key principle: Each dose should be tolerated for at least 4 weeks before escalation. If GI side effects are unmanageable at any level, hold or reduce rather than pushing through. The therapeutic effect builds over months, not weeks.

Lean mass preservation

The STEP trials reported approximately 40% lean mass loss as a proportion of total weight lost — consistent with any caloric-deficit-induced weight loss at this magnitude. Lean mass preservation requires active intervention:

• Resistance training: 2–3 sessions per week minimum, focusing on compound movements. This is the single most important countermeasure against lean mass loss.
• Protein intake: Minimum 1.6 g/kg of target body weight daily. Some providers target 2.0 g/kg. Protein intake should increase as appetite decreases — this requires deliberate effort when semaglutide is suppressing hunger.
• Creatine monohydrate: 3–5 g daily. Low-risk, well-characterized supplement that supports muscle protein synthesis and exercise performance during caloric deficit.

Managing side effects

• Nausea: Most common in first 4–8 weeks. Eating smaller, more frequent meals helps. Avoid fatty/fried food. Ginger tea or ginger supplements have modest evidence.
• Constipation: Due to slowed gastric emptying. Increase fiber intake, hydration, and consider magnesium citrate supplementation (200–400 mg at bedtime).
• Fatigue: Usually resolves as the body adapts. Ensure adequate caloric intake — severe restriction on top of semaglutide can create problematic energy deficits.
• Injection site reactions: Rotate injection sites (abdomen, thigh, upper arm). Mild redness is common and transient.

Expected timeline

Months 1–3: 3–5% body weight loss. Appetite suppression is the primary driver. Body composition changes may not be visible yet.

Months 4–8: 8–12% body weight loss. Visible changes in waist circumference, face, and clothing fit. Metabolic markers (fasting glucose, A1C, triglycerides, blood pressure) typically improve.

Months 9–16: 12–17% body weight loss at maximum dose. The rate of loss slows as a new equilibrium is approached. This is normal — not a plateau to push through.

Long-term strategy

The STEP-1 extension data showed that approximately two-thirds of weight lost is regained within one year of discontinuation. This informs the long-term decision framework:

Option 1: Maintenance dose. Reduce to the lowest effective dose (often 0.5–1.0 mg/week) rather than discontinuing entirely. This preserves appetite regulation with lower drug exposure and cost.

Option 2: Lifestyle transition. Discontinue after achieving target weight, but with intensive behavioral support, maintained resistance training, and high protein intake. Expect some regain; the goal is to retain the majority of metabolic benefits.

Option 3: Indefinite treatment. Treat semaglutide like a chronic medication (similar to statins or antihypertensives). This reflects the emerging clinical consensus that obesity is a chronic disease requiring chronic treatment.

Evidence context

Semaglutide for weight management is one of the best-characterized pharmacological interventions in modern medicine. The STEP program comprises multiple Phase 3 trials with thousands of participants. The SELECT cardiovascular outcomes trial showed a 20% reduction in major adverse cardiovascular events. This is not a research peptide with preliminary data — it is a validated pharmaceutical with robust outcome evidence.